2024
Implementation and evaluation of an electronic consult program at a large academic health system
Arora A, Fekieta R, Spatz E, Roy B, Marco K, Sharifi M, Pashankar D, Khokhar B. Implementation and evaluation of an electronic consult program at a large academic health system. PLOS ONE 2024, 19: e0310122. PMID: 39264980, PMCID: PMC11392322, DOI: 10.1371/journal.pone.0310122.Peer-Reviewed Original ResearchConceptsAcademic health systemHealth systemEConsult programBenefits of eConsultEffective implementation strategiesPrimary careElectronic consultationSpecialist cliniciansSpecialty cliniciansEngaging leadershipHigh satisfactionImplementation strategiesCapture satisfactionIncrease accessConsultation programProcess outcomesEConsultsQuality assurance mechanismsSurgical specialtiesSpecialtyQuantitative dataMulti-method approachCliniciansSatisfactionProgram
2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, Aronow J, Bass D, Bass J, Benkov K, Tobi C, Boccieri M, Boyle B, Brinkman W, Cabera J, Chun K, Colletti R, Dodds C, Dorsey J, Ebach D, Entrena E, Forrest C, Galanko J, Grunow J, Gulati A, Ivanova A, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Lipstein E, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Osaba L, Palomo P, Pappa H, Park K, Pashankar D, Pitch L, Robinson M, Samson C, Sandberg K, Schuchard J, Seid M, Shelly K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Zikry M, Weinberger M, Saeed S, Bousvaros A. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial. Gastroenterology 2023, 165: 149-161.e7. PMID: 37004887, PMCID: PMC10330864, DOI: 10.1053/j.gastro.2023.03.224.Peer-Reviewed Original ResearchConceptsPediatric Crohn's diseaseNecrosis factor inhibitorsPatient-reported outcomesAdverse eventsTreatment failureCombination therapyCrohn's diseaseSerious AEsFactor inhibitorsTumor necrosis factor inhibitorsAnti-drug antibody developmentAnti-TNF monotherapyCombination therapy armCrohn's disease therapyMethotrexate combination therapyTolerable safety profileLow-dose methotrexateMore adverse eventsSerious adverse eventsAnti-drug antibodiesPragmatic Randomized TrialDisease therapyLoss of responseOral methotrexateTherapy armUse, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere diseaseAnalysis of Failure Rates for COVID-19 Entrance Screening at a US Academic Medical Center
Roberts S, Faruq R, Wilkinson A, Pashankar D, Russi M, Khokhar B, Martinello R. Analysis of Failure Rates for COVID-19 Entrance Screening at a US Academic Medical Center. JAMA Internal Medicine 2023, 183: 84-86. PMID: 36441528, PMCID: PMC9706395, DOI: 10.1001/jamainternmed.2022.5426.Peer-Reviewed Original Research
2022
Isolated Terminal Ileitis in Children
Alper A, Bennett A, Rottmann D, Morotti R, Escalera S, Phatak U, Pashankar D. Isolated Terminal Ileitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2022, 76: 338-342. PMID: 36729703, DOI: 10.1097/mpg.0000000000003679.Peer-Reviewed Original ResearchConceptsCrohn's diseaseTerminal ileitisAbnormal C-reactive protein levelsC-reactive protein levelsBowel wall thickeningLong-term outcomesRadiological evidenceRadiological featuresSevere inflammationPediatric literatureHigh prevalenceIleitisWall thickeningProtein levelsChildrenPrevalenceAdultsColonoscopyInflammationEndoscopicHistologicDiseaseMonths
2021
Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease
Miller T, Schuchard J, Carle A, Forrest C, Kappelman M, Group T, Adler J, Ammoury R, Bass D, Bass J, Benkov K, Bousvaros A, Boyle B, Cabrera J, Colletti R, Dorsey J, Ebach D, Firestine A, Gulati A, Hoffenberg E, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Rios Z, Moses J, Palomo P, Pappa H, Pashankar D, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease. The Journal Of Pediatrics 2021, 242: 86-92.e3. PMID: 34740588, PMCID: PMC8882140, DOI: 10.1016/j.jpeds.2021.10.053.Peer-Reviewed Original ResearchConceptsPROMIS pediatric measuresMulticenter pragmatic trialCrohn's diseasePediatric measuresClinical trialsDisease activityPain interferencePragmatic trialPediatric patient-reported outcome measuresPatient-reported outcome measuresLower PRO scoresOutcomes Measurement Information System (PROMIS) pediatric measuresPRO score changesSteroid-free remissionPediatric Crohn's diseaseChronic pediatric illnessPragmatic clinical trialsClinical trial endpointsUse of patientPediatric patientsStudy endpointClinical outcomesPRO scoresTrial endpointsPRO endpoints
2020
Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure
Gupta N, Liu C, King E, Sylvester F, Lee D, Boyle B, Trauernicht A, Chen S, Colletti R, Adler J, Ali S, Al-Nimr A, Ayers T, Baron H, Beasley G, Benkov K, Cabrera J, Cho-Dorado M, Dancel L, Di Palma J, Dorsey J, Gulati A, Hellmann J, Higuchi L, Hoffenberg E, Israel E, Jester T, Kiparissi F, Konikoff M, Leibowitz I, Maheshwari A, Moulton D, Moses J, Ogunmola N, Palmadottir J, Pandey A, Pappa H, Pashankar D, Pasternak B, Patel A, Quiros J, Rountree C, Samson C, Sandberg K, Schoen B, Steiner S, Stephens M, Sudel B, Sullivan J, Suskind D, Tomer G, Tung J, Verstraete S. Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure. Inflammatory Bowel Diseases 2020, 26: 1880-1889. PMID: 31968095, DOI: 10.1093/ibd/izz334.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseGrowth plate closureUlcerative colitisCrohn's diseaseAge 15 yearsPlate closureStatural growthHeight gainNutrition Examination SurveyFinal adult heightHeight velocity curvesTotal height gainBowel diseasePediatric patientsExamination SurveyPatient transitionsNational HealthAdult carePatientsDisease statusAdult heightDiseaseYoung adultsGrowth plateRadiographic closure
2018
Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease
Phatak U, Rojas‐Velasquez D, Pashankar DS. Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease. Journal Of Pediatric Gastroenterology And Nutrition 2018, 66: e137-e137. PMID: 29287017, DOI: 10.1097/mpg.0000000000001885.Peer-Reviewed Original Research
2017
Correlation of Erythrocyte Sedimentation Rate and C‐Reactive Protein With Pediatric Inflammatory Bowel Disease Activity
Alper A, Zhang L, Pashankar DS. Correlation of Erythrocyte Sedimentation Rate and C‐Reactive Protein With Pediatric Inflammatory Bowel Disease Activity. Journal Of Pediatric Gastroenterology And Nutrition 2017, 65: e25-e27. PMID: 27741061, DOI: 10.1097/mpg.0000000000001444.Peer-Reviewed Original ResearchConceptsErythrocyte sedimentation rateC-reactive proteinInflammatory bowel diseaseDisease activityCrohn's diseaseBowel diseaseCRP valuesInflammatory bowel disease activitySmall bowel Crohn's diseaseUlcerative colitis disease activityNormal erythrocyte sedimentation rateBowel disease activityRadiographic disease activityHistologic activitySedimentation rateUlcerative colitisDiseaseDiagnosisChildrenColitisActivityPrevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease
Phatak UP, Rojas‐Velasquez D, Porto A, Pashankar DS. Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease. Journal Of Pediatric Gastroenterology And Nutrition 2017, 64: 261-264. PMID: 27846066, DOI: 10.1097/mpg.0000000000001474.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBowel diseaseYoung adultsAdverse effectsMarijuana useNeuropsychiatric adverse effectsPediatric IBD clinicsHalf of patientsPossible adverse effectsIBD clinicIBD therapyAbdominal painDisease activityIBD symptomsPoor appetiteMedical therapySymptom reliefComplete reliefSymptom improvementPatientsNonusers of marijuanaUse of marijuanaAnonymous questionnaireMedical marijuanaLegalization of marijuana
2016
Calcific Pancreatitis in Children
Patel MG, Baker K, Phatak UP, Alper A, Pashankar DS. Calcific Pancreatitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2016, 62: e28-e29. PMID: 24979475, DOI: 10.1097/mpg.0000000000000470.Peer-Reviewed Original ResearchPrevalence and Clinical, Endoscopic, and Pathological Features of Duodenitis in Children
Alper A, Hardee S, Rojas‐Velasquez D, Escalera S, Morotti RA, Pashankar DS. Prevalence and Clinical, Endoscopic, and Pathological Features of Duodenitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2016, 62: 314-316. PMID: 26252915, PMCID: PMC4724230, DOI: 10.1097/mpg.0000000000000942.Peer-Reviewed Original ResearchConceptsAssociated gastritisEndoscopic appearancePathological featuresCeliac diseaseClinical diagnosisDiagnosis of duodenitisPositive celiac serologyInflammatory bowel diseaseHelicobacter pylori infectionPatient's clinical diagnosisCeliac serologyAbdominal painUpper endoscopyVillous changesBowel diseaseCommon indicationUlcerative colitisCommon etiologyCrohn's diseasePylori infectionPathology reportsDuodenitisCommon causeEndoscopic dataLarge cohort
2015
Obesity and Gastrointestinal Disorders in Children
Phatak UP, Pashankar DS. Obesity and Gastrointestinal Disorders in Children. Journal Of Pediatric Gastroenterology And Nutrition 2015, 60: 441-445. PMID: 25493349, DOI: 10.1097/mpg.0000000000000670.Peer-Reviewed Original ResearchConceptsGastrointestinal disordersCommon GI disordersOrganic GI diseaseAssociation of obesityFunctional gastrointestinal disordersInflammatory bowel diseaseGI disordersBowel diseaseObese childrenGI diseaseCeliac diseasePossible complicationsComprehensive careClinical significanceObesityDiseaseDisordersChildrenGlobal pandemicAssociationPresent dataRecent studiesPossible mechanismComplicationsPhysicians
2014
Histopathology of Duodenal Mucosal Lesions in Pediatric Patients with Inflammatory Bowel Disease: Statistical Analysis to Identify Distinctive Features
Hardee S, Alper A, Pashankar DS, Morotti RA. Histopathology of Duodenal Mucosal Lesions in Pediatric Patients with Inflammatory Bowel Disease: Statistical Analysis to Identify Distinctive Features. Pediatric And Developmental Pathology 2014, 17: 450-454. PMID: 25207874, DOI: 10.2350/14-07-1529-oa.1.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal tractVillous bluntingIntraepithelial lymphocytesPediatric patientsDuodenal lesionsDifferent etiopathogenesisUlcerative colitisCrohn's diseaseInflammatory bowel disease patientsCases of duodenitisDuodenal mucosal lesionsBowel disease patientsInflammatory bowel diseasePresence of granulomasAge-matched controlsLamina propria eosinophilsKruskal-Wallis testingCeliac groupDuodenal pathologyDuodenitis casesAssociated gastritisBowel diseaseCrypt hyperplasiaMucosal lesionsPediatric populationIndividual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology
Vilarinho S, Choi M, Jain D, Malhotra A, Kulkarni S, Pashankar D, Phatak U, Patel M, Bale A, Mane S, Lifton RP, Mistry PK. Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology. Journal Of Hepatology 2014, 61: 1056-1063. PMID: 25016221, PMCID: PMC4203706, DOI: 10.1016/j.jhep.2014.06.038.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBase SequenceCarboxylic Ester HydrolasesChildCholestasisDNA Mutational AnalysisEnd Stage Liver DiseaseExomeFatal OutcomeFemaleGenes, RecessiveHepatolenticular DegenerationHeterozygoteHomozygoteHumansInfant, NewbornLiver FailureLiver Failure, AcuteMaleMembrane ProteinsMitochondrial ProteinsMolecular Sequence DataPedigreeReceptor, Notch2RNA Splice SitesSequence Homology, Amino AcidConceptsFatal acute liver failureWhole-exome sequencingAdvanced liver diseaseAcute liver failureIndeterminate etiologyYear old femaleLiver failureLiver diseaseMetabolic liver diseasePatient 3Treatment optionsPhenotypic spectrumPediatric liver failureDecompensated liver cirrhosisManagement of childrenOptimal treatment optionsAge 3 monthsNovel inborn errorLiver transplantAtypical presentationLiver cirrhosisHepatocerebral mitochondrial DNA depletion syndromePatient 1Patient 2Unknown etiology
2001
Effect of Long-term Omeprazole Treatment on Antral G and D Cells in Children
Pashankar D, Israel D, Jevon G, Buchan A. Effect of Long-term Omeprazole Treatment on Antral G and D Cells in Children. Journal Of Pediatric Gastroenterology And Nutrition 2001, 33: 537-542. PMID: 11740225, DOI: 10.1097/00005176-200111000-00005.Peer-Reviewed Original ResearchConceptsLong-term omeprazole therapyD cell numbersAge-matched control groupG-cell numberOmeprazole therapyControl groupD cellsEndoscopic antral biopsy specimensAge groupsLong-term omeprazole treatmentErosive reflux esophagitisAntral biopsy specimensEffect of omeprazoleSignificant increaseDifferent age groupsReflux esophagitisGastrin secretionOmeprazole administrationBiopsy specimensHealthy childrenOmeprazole treatmentParacrine mannerOmeprazoleAntral glandsTherapyEfficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children
Pashankar D, Bishop W. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. The Journal Of Pediatrics 2001, 139: 428-432. PMID: 11562624, DOI: 10.1067/mpd.2001.117002.Peer-Reviewed Original ResearchConceptsChronic constipationStool frequencyStool consistencyOptimal dosePolyethylene glycol 3350Weekly stool frequencyTreatment of constipationMean effective doseFisher's exact testSignificant adverse effectsStudent's t-testFecal retentionSoft stoolDaily administrationInitial doseMean doseConstipationExact testEffective doseDoseAdverse effectsT-testChildrenTreatmentEfficacyJaundice in Older Children and Adolescents
Pashankar D, Schreiber R. Jaundice in Older Children and Adolescents. Pediatrics In Review 2001, 22: 219-226. PMID: 11435623, DOI: 10.1542/pir.22-7-219.Peer-Reviewed Original ResearchOmeprazole Maintenance Therapy for Gastroesophageal Reflux Disease After Failure of Fundoplication
Pashankar D, Blair G, Israel D. Omeprazole Maintenance Therapy for Gastroesophageal Reflux Disease After Failure of Fundoplication. Journal Of Pediatric Gastroenterology And Nutrition 2001, 32: 145-149. PMID: 11321383, DOI: 10.1097/00005176-200102000-00010.Peer-Reviewed Original ResearchConceptsSymptoms of GERGastroesophageal refluxGastroesophageal reflux diseaseReflux diseaseRecurrence of GERFailure of fundoplicationGrade II esophagitisLong-term omeprazoleOmeprazole maintenance therapySeverity of esophagitisClinical adverse effectsSevere gastroesophageal refluxSubsequent surgical interventionLong-term drugsBenign gastric polypsMaintenance therapyPeptic strictureEsophageal dilatationFurther surgeryHiatal herniaTherapeutic challengeSurgical interventionGastric polypsMean ageClinical assessment
2000
Efficacy and safety of long-term omeprazole treatment
Pashankar D. Efficacy and safety of long-term omeprazole treatment. Gastroenterology 2000, 119: 1177-1178. PMID: 11203032, DOI: 10.1053/gast.2000.19222.Peer-Reviewed Original Research